Pharvaris (PHVS) Enterprise Value (2019 - 2026)
Pharvaris (PHVS) posted Enterprise Value of -$289.1 million for Q1 2026, up 14.84% on a QoQ basis from -$339.5 million in Q4 2025, and down 16.22% year-over-year from -$345.1 million in Q1 2025.
Pharvaris (PHVS) Enterprise Value (2019 - 2026) Analysis & Trends
Pharvaris' Enterprise Value history runs 8 years deep, the most recent figure standing at -$289.1 million for Q1 2026.
- Quarterly Enterprise Value fell 16.22% year-over-year to -$289.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$289.1 million (down 16.22% YoY) and the FY2025 annual result came in at -$329.5 million, down 8.46% from the prior year.
- Enterprise Value was -$289.1 million for Q1 2026 at Pharvaris, up from -$339.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$145.1 million in Q1 2023 and bottomed at -$420.9 million in Q4 2023.
- A 5-year average of -$272.1 million and a median of -$248.8 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value tumbled 175.79% — and 2025, when it surged 38.94%.
- Pharvaris' Enterprise Value stood at -$165.1 million in 2022, then sank by 154.94% to -$420.9 million in 2023, then rose by 28.73% to -$300.0 million in 2024, then slipped by 13.18% to -$339.5 million in 2025, then gained by 14.84% to -$289.1 million in 2026.
- Business Quant data shows PHVS's Enterprise Value at -$289.1 million in Q1 2026, -$339.5 million in Q4 2025, and -$385.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - | -289.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -289.13 Mn |
| Dec 31, 2025 | -339.53 Mn |
| Sep 30, 2025 | -384.95 Mn |
| Jun 30, 2025 | -225.91 Mn |
| Mar 31, 2025 | -248.77 Mn |
| Dec 31, 2024 | -299.98 Mn |
| Sep 30, 2024 | -335.17 Mn |
| Jun 30, 2024 | -369.99 Mn |
| Mar 31, 2024 | -400.15 Mn |
| Dec 31, 2023 | -420.94 Mn |
| Sep 30, 2023 | -172.39 Mn |
| Jun 30, 2023 | -195.12 Mn |
| Mar 31, 2023 | -145.10 Mn |
| Dec 31, 2022 | -165.11 Mn |
| Sep 30, 2022 | -199.37 Mn |
| Jun 30, 2022 | -214.89 Mn |
| Mar 31, 2022 | -218.60 Mn |
| Dec 31, 2021 | -239.49 Mn |
| Sep 30, 2021 | -257.79 Mn |
| Jun 30, 2021 | -270.14 Mn |